Back to Search Start Over

Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC)

Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC)

Authors :
Nazli Dizman
Ameish Govindarajan
Zeynep Busra Zengin
Luis A Meza
Nishita Tripathi
Nicolas Sayegh
Daniela V. Castro
Elyse H. Chan
Kyle O. Lee
Sweta R. Prajapati
Matthew I. Feng
Vivian Loo
Makala Pace
Shea O'brien
Erin B. Bailey
Regina Barragan-Carrillo
Alex Chehrazi-Raffle
Xiaochen Li
Neeraj Agarwal
Sumanta Monty Pal
Source :
Journal of Clinical Oncology. 41:678-678
Publication Year :
2023
Publisher :
American Society of Clinical Oncology (ASCO), 2023.

Abstract

678 Background: Recent studies have suggested an association between the time-of-day of ICI infusions and disease outcomes, including progression free survival and overall survival, among patients with cancer. (Qian et al Lancet Oncology 2021). We sought to identify whether such an association exists in patients with mRCC receiving ICIs. Methods: Patients with mRCC treated with nivolumab alone, or in combination with ipilimumab, in either first- or second-line treatment were retrospectively identified. Patients who received

Subjects

Subjects :
Cancer Research
Oncology

Details

ISSN :
15277755 and 0732183X
Volume :
41
Database :
OpenAIRE
Journal :
Journal of Clinical Oncology
Accession number :
edsair.doi...........9cdb62284ec655e17f13ec7ee327ee09
Full Text :
https://doi.org/10.1200/jco.2023.41.6_suppl.678